1. Pancreatic cancer or suspected pancreatic cancer 2. Neither pancreatic cancer nor other cancers Pancreatic cancer
Conditions
Sponsors
Yachida Shinichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient-provided informed consent and over 20 years old 2. Patients with pancreatic cancer or suspected of pancreatic cancer (N=100) and Participants without pancreatic cancer or other cancers (N=50) (Planned endoscopy) 3. Persons who have given their written consent to participate in this research
Exclusion criteria
Exclusion criteria: 1) Patients with hypersensitivity to secretin or other ingredients (excipients: cysteine hydrochloride and mannitol) 2) Patients in remission from acute pancreatitis or acute exacerbations of chronic pancreatitis within 2 weeks of the start of administration of the study drug 3) Patients who don't discontinue anticholinergic drugs at least 5 half-lives prior to the start of administration of the study drug 4) Pregnant or lactating women 5) Patients who received other research drugs or investigational drugs within 3 months of the start of administration of the study drug 6) Patients whom the doctor in charge judges inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity and specificity of pancreatic cancer diagnosis | — |
Secondary
| Measure | Time frame |
|---|---|
| Volume of the collected duodenal juice Adverse events within next day after administration of the study drug | — |
Contacts
Public ContactHidenori Tanaka
Graduate School of Medicine, Osaka University
Outcome results
None listed